Name:
(Positional Isomer: MDMB) 3-Fluoro-N-methylcathinone (3-FMC)
Type:
AKA:
N/A
(Positional Isomer: MDMB) 3-Fluoro-N-methylcathinone (3-FMC) image
Synthetic substance, no natural derivative
IUPAC Logo
Positional Isomer: MDMB 3-Fluoro-N-methylcathinone (3-FMC) image
FMC was first synthesized in 1949 by the German chemist Friedrich W. Miescher (1895–1962) who was awarded the Nobel Prize in Chemistry in 1953 for his work on the synthesis of quinoline and pyridine derivatives. Miescher’s group first prepared FMC by a series of reactions with substituted o-anisyl chloride, using phosphorus trichloride as a catalyst. This resulted in the formation of the corresponding cyclohexanone derivatives. In 1951, Miescher and his group synthesized the related 1,3-dimethyl-3-fluorophenyl-1,3-dimethylbutan-2-one (1,3-difluorophenyl-1,3-dimethylbutan-2-one or 1,3-difluorobenzene) which had been obtained by the group of Henry S. Bloch (1907–
Synthetic Substances Image
Short-term effects of 3 fmc Long-term effects of 3 fmc Medical applications of 3 fmc Potential risks of 3 fmc The primary physical effects of 3 fluoro n methylcathinone (3 fmc) include: Reduced heart rate, blood pressure, and respiratory rate. Increased blood flow to the brain, particularly to the cerebral cortex. Reduced body temperature. Increased
N/A
N/A
N/A
3-Fluoro-N-Methylcathinone (3-FMC) is a synthetic cathinone with no historical lore but emerged in the 21st century. It is known for its recreational use and associated health risks. Proponents discuss its stimulant effects, while opponents focus on potential dangers and regulatory challenges. Its use is primarily recreational, reflecting broader concerns about synthetic drugs.
N/A